Boehringer Ingelheim Acquires Vira Therapeutics Stakes for Development of Immuno- Oncology Viral Therapies

 Boehringer Ingelheim Acquires Vira Therapeutics Stakes for Development of Immuno- Oncology Viral Therapies

Boehringer Ingelheim Acquires Vira Therapeutics Stakes for Development of Immuno- Oncology Viral Therapies

Shots:

  • The total acquisition value is based on option and share agreement i.e. EUR 210M signed in 2016 b/w two companies. Under the deal ViraTherapeutics will operate in Innsbruck, Austria as a unit of BI’s Discovery Research organization
  • The focus of this deal is to develop innovative viral-based oncology treatments for transforming the lives of cancer patients and improving their QoL
  • Vira is a combination of two investors EMBL Ventures and the BIVF. BIVF has EUR 250M under management and supervises unit of 22 active companies

Click here to read full press release/ article | Ref: Boehringer | Image: Adapt

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post